InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,446.68
(
0.00%
)
US TECH 100
17,981.20
(
-2.20%
)
Dow Jones
40,347.97
(
0.00%
)
Brent Oil
77.99
(
-2.48%
)
Bitcoin
64,714.95
(
-0.97%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120193
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: bladerunner1717 post# 4464

Wednesday, 12/29/2010 10:56:10 PM

Wednesday, December 29, 2010 10:56:10 PM

Post# of 80490
For oncology indications only, Afinitor’s 3Q10 annualized run rate was $270M (#msg-56352208); including Zortress/Certican, which is the same drug for non-oncology indications, the 3Q10 annualized run rate was $410M.

p.s. Afinitor has only one “f”.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up